Skip to Content

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

Treatment with a novel Cereblon E3 Ligase Modulator Agent, in Combination with Dexamethasone and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma, achieves an ORR of 73,7 %. In this MEDtalk Professor Paul G. Richardson presents the data, and results on how combination therapy shows immune-stimulatory effects in patients with Relapsed/Refractory Multiple Myeloma.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top